Prostate-specific antigen screening: pro (Q37707943)

22 August 2017

1 reference

title

Prostate-specific antigen screening: pro (English)

1 reference

22 August 2017

1

1 reference

22 August 2017

William J Catalona

2

1 reference

22 August 2017

1 May 2010

1 reference

Current Opinion in Urology

22 August 2017

1 reference

22 August 2017

20

1 reference

22 August 2017

3

1 reference

22 August 2017

185-188

1 reference

Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Prostate-cancer screening

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Screening and prostate-cancer mortality in a randomized European study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Mortality results from a randomized prostate-cancer screening trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Quantifying the role of PSA screening in the US prostate cancer mortality decline

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572789

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

3 December 2018

1 reference

12 December 2020

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

12 December 2020

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

12 December 2020

Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease

1 reference

12 December 2020

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

1 reference

12 December 2020

Prostate specific antigen density correlates with features of prostate cancer aggressiveness

1 reference

12 December 2020

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach

1 reference

12 December 2020

10.1097/MOU.0B013E3283384047

Identifiers

DOI

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

PMCID

3572789